What TRIMTECH Therapeutics does

TRIMTECH Therapeutics Ltd. is a Cambridge, UK-based biotechnology company founded in 2023 that develops small molecule targeted protein degraders for neurodegenerative and inflammatory diseases. The company's proprietary platform exploits TRIM21, an underexploited E3 ubiquitin ligase, to selectively degrade disease-causing protein aggregates (such as tau oligomers and fibrils in Alzheimer's, Parkinson's, and Huntington's disease) while preserving functional monomeric proteins. Two complementary modalities sit on this platform: TRIMTAC®, bispecific chimeric degraders that recruit TRIM21 to aggregated targets, and TRIMGLUE®, molecular glue degraders that exploit cryptic mutual binding interactions and can address targets lacking known ligands.

The company's intellectual property is anchored in 20+ years of academic research by co-founders Leo James (MRC Laboratory of Molecular Biology) and Will McEwan (UK Dementia Research Institute, University of Cambridge), supported by peer-reviewed publications in Science, Cell, and PNAS. The leadership team combines these founders with experienced biotech operators: CEO Nicki Thompson (formerly founding CEO of Amphista Therapeutics, ~$150M raised, $2.3Bn in pharma deals) and Chair Alison Lawton (former CEO of Kaleido Biosciences who led its IPO). The SAB is chaired by Prof. Alessio Ciulli (FRS), a foundational figure in targeted protein degradation.

TRIMTECH is a pre-revenue, preclinical-stage company with no commercialized products and 1–10 employees. Its go-to-market motion follows the standard biotech partnering model: advance compounds through preclinical and IND-enabling stages internally and either license or co-develop with larger pharmaceutical partners. The company has raised $47M in seed funding across two tranches (March 2025: $31M led by Cambridge Innovation Capital and SV Health Investors' Dementia Discovery Fund; June 2026: $14M extension led by Johnson & Johnson Innovation – JJDC and BGF), with strategic pharma investors including Pfizer Ventures, M Ventures, and Eli Lilly taking board seats.

Name

TRIMTECH Therapeutics

Legal name

TRIMTECH Therapeutics Ltd.

Website

https://trimtechtherapeutics.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

1–10 employees

Short description

TRIMTECH Therapeutics is a Cambridge, UK-based preclinical biotech developing TRIM21-based small molecule targeted protein degraders (TRIMTAC® and TRIMGLUE®) to selectively eliminate toxic protein aggregates causing neurodegenerative and inflammatory diseases. Founded in 2023 with $47M seed funding and pharma backing from J&J, Pfizer, and Eli Lilly.

Ownership category

akta.pro rank

Product category

Neurodegenerative Disease Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

akta.pro secondary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

Keywords

• Targeted protein degradation
• Small molecule therapeutics
• Neurodegenerative disease drug discovery
• CNS-penetrant degraders
• TRIM21 E3 ligase platform

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Therapeutic Development and Commercialization: Pre-revenue biotech company developing small molecule drugs for neurodegenerative diseases. Revenue will likely come from product sales following regulatory approval, or through licensing/partnership deals with pharmaceutical companies during development.

Go-to-market motion1 record

Marketing channels6 records

Core offering

TRIMTECH Therapeutics develops novel small molecule targeted protein degraders (TRIMTAC® and TRIMGLUE®) that leverage the TRIM21 E3 ubiquitin ligase to selectively degrade disease-causing protein aggregates in the brain. The company is building a pipeline of CNS-penetrant therapeutics targeting neurodegenerative and inflammatory disorders such as Alzheimer's, Parkinson's, and Huntington's disease.

Product overview

TRIMTECH Therapeutics is developing a differentiated portfolio of potent, highly specific small molecule targeted protein degraders for the treatment of neurodegenerative and inflammatory diseases. The company's proprietary platforms consist of TRIMTAC® (bispecific heterobifunctional degraders) and TRIMGLUE® (molecular glue degraders), both leveraging the unique mechanism of TRIM21 E3 ligase to selectively degrade toxic protein aggregates while preserving functional monomeric proteins. These two platforms work together to address protein aggregation disorders affecting the CNS and inflammatory conditions.

Differentiator

Problem solved

Functional benefit

Products and services

• TRIMTAC® Degraders Bispecific 'chimeric' small molecule degraders that recruit the TRIM21 E3 ligase to disease-causing aggregated protein targets for selective degradation via the ubiquitin-proteasome system, while preserving functional monomeric proteins.
• TRIMGLUE® Degraders Small molecule molecular glue degraders that exploit cryptic mutual binding interactions to bring protein targets and TRIM21 together, applicable where no suitable ligands are known for the target, enabling degradation of previously intractable protein aggregates.

Quantifiable outcome

• Demonstrated degradation of pathological tau aggregates and oligomers in preclinical models while preserving functional monomeric tau
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered minor.

• BioMed RealtyminorStrategic or Co-development Partner · 24 February 2026Real estate partner at Babraham Research Campus. BioMed Realty completed lease-up of newest laboratory building with TRIMTECH and Tagomics signing leases for fully fitted laboratory and office space.
• Babraham Research Campus LtdminorStrategic or Co-development Partner · 24 February 2026Landlord and research campus operator providing laboratory and office facilities to TRIMTECH as tenant. Supports early-stage and scaling life science companies within one of Europe's most established research ecosystems.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/trimtech-therapeutics-limited

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds2 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TRIMTECH Therapeutics